Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNZ132-1-40 in healthy adults
NCT03239379Phase 1Completed
- Sponsor
- Bioniz Therapeutics, Inc.
- Start
- Oct 2017
- Primary completion
- Feb 2018
- Modality
- Small Molecules, PEGylated Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in T-cell large granular lymphocytic leukemia, cutaneous T-cell lymphoma (CTCL) and alopecia areata comparing BNZ132-1-40 with Placebo (2 arms). Primary endpoint: Incidence, severity and relationship of treatment-emergent adverse events at 8 weeks. Started Oct 2017; status: completed.
02
Drugs
BNZ-1
03
Conditions
T-cell large granular lymphocytic leukemiacutaneous T-cell lymphoma (CTCL)alopecia areata
Beyond the preview
Go deeper on NCT03239379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03239379.